Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis by Hans-Theo Schon et al.
REVIEW
published: 24 February 2016
doi: 10.3389/fphar.2016.00033
Edited by:
Kotambail Venkatesha Udupa,
University College Dublin and St
Vincent’s University Hospital, Ireland
Reviewed by:
Lydia E. Matesic,
University of South Carolina, USA
Satish Ramalingam,
Chettinad Academy of Research
and Education, India
*Correspondence:
Ralf Weiskirchen
rweiskirchen@ukaachen.de
Specialty section:
This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 01 December 2015
Accepted: 08 February 2016
Published: 24 February 2016
Citation:
Schon H-T, Bartneck M,
Borkham-Kamphorst E,
Nattermann J, Lammers T, Tacke F
and Weiskirchen R (2016)
Pharmacological Intervention
in Hepatic Stellate Cell Activation
and Hepatic Fibrosis.
Front. Pharmacol. 7:33.
doi: 10.3389/fphar.2016.00033
Pharmacological Intervention in
Hepatic Stellate Cell Activation and
Hepatic Fibrosis
Hans-Theo Schon1, Matthias Bartneck2, Erawan Borkham-Kamphorst1,
Jacob Nattermann3, Twan Lammers4, Frank Tacke2 and Ralf Weiskirchen1*
1 Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, RWTH University Hospital
Aachen, Aachen, Germany, 2 Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany,
3 Department of Internal Medicine I, University of Bonn, Bonn, Germany, 4 Department for Experimental Molecular Imaging,
University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany
The activation and transdifferentiation of hepatic stellate cells (HSCs) into contractile,
matrix-producing myofibroblasts (MFBs) are central events in hepatic fibrogenesis.
These processes are driven by autocrine- and paracrine-acting soluble factors (i.e.,
cytokines and chemokines). Proof-of-concept studies of the last decades have shown
that both the deactivation and removal of hepatic MFBs as well as antagonizing
profibrogenic factors are in principle suitable to attenuate ongoing hepatic fibrosis.
Although several drugs show potent antifibrotic activities in experimental models of
hepatic fibrosis, there is presently no effective pharmaceutical intervention specifically
approved for the treatment of liver fibrosis. Pharmaceutical interventions are generally
hampered by insufficient supply of drugs to the diseased liver tissue and/or by adverse
effects as a result of affecting non-target cells. Therefore, targeted delivery systems that
bind specifically to receptors solely expressed on activated HSCs or transdifferentiated
MFBs and delivery systems that can improve drug distribution to the liver in general are
urgently needed. In this review, we summarize current strategies for targeted delivery
of drugs to the liver and in particular to pro-fibrogenic liver cells. The applicability and
efficacy of sequestering molecules, selective protein carriers, lipid-based drug vehicles,
viral vectors, transcriptional targeting approaches, therapeutic liver- and HSC-specific
nanoparticles, and miRNA-based strategies are discussed. Some of these delivery
systems that had already been successfully tested in experimental animal models of
ongoing hepatic fibrogenesis are expected to translate into clinically useful therapeutics
specifically targeting HSCs.
Keywords: liver disease, drug targeting, gene therapy, differential expression, biomedicine, antifibrotic,
fibrogenesis, translational medicine
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CHARACTERIZATION AND
SIGNIFICANCE OF LIVER FIBROSIS
Hepatic ﬁbrosis is a naturally occurring wound healing reaction,
driven by inﬂammation, which in turn is caused by persistent
parenchymal injury. The main causes of hepatic damage are
chronic hepatitis B and hepatitis C virus infections, alcohol
abuse, biliary obstruction, autoimmune disease, hereditary
haemochromatosis, and NAFLD (Ramachandran and Iredale,
2012). Untreated liver ﬁbrosis ultimatively progresses to cirrhosis
and increases the risk of developing HCC. Both hepatic ﬁbrosis
and cirrhosis are crucial causes of global morbidity and mortality
(Iredale, 2007) and the incidence of advanced ﬁbrosis in a cohort
of 7000 persons was roughly estimated to be 2.8% (Poynard
et al., 2010). Because there are no eﬀective antiﬁbrotic treatments
available, there is an urgent need to develop such interventions,
particularly given the progressive character and high prevalence
of this disease.
The liver is made up of parenchymal and non-parenchymal
cells (PCs). Hepatocytes are the only PC type, whereas KCs,
LSECs, HSCs, also referred to as Ito or fat storing cells, and biliary
epithelial cells belong to the group of non-PCs (Kmiec´, 2001;
Chen and Sun, 2011). In addition, the liver is enriched with a
large variety of immune cells, including circulating intrahepatic
lymphocytes and liver resident dendritic cells (Racanelli and
Rehermann, 2006). In regard to hepatic ﬁbrosis, HSCs are of
particular importance, because this cell type is the source of
the majority of MFBs (Povero et al., 2010). In their quiescent
state, HSCs store vitamin A and retinoids, but upon tissue
damage they undergo a transition to MFBs, a process that is
commonly known as transdiﬀerentiation. This process is induced
by soluble mediators, including TGF-β1, PDGF, and TNF (Schon
and Weiskirchen, 2014). After injury, these factors are released
by hepatocytes, by activated KCs (Cubero and Nieto, 2006) and
by inﬂammatory monocyte-derived macrophages (Zimmermann
et al., 2010). The activated MFBs are highly proliferative, have
the ability to migrate, and synthesize components of the ECM
Abbreviations: α-SMA, α-smooth muscle actin; Ad, adenovirus; BDNF,
brain-derived growth factor; BiPPB, bicyclic PDGFβR-binding peptide; BSA,
bovine serum albumin; CAR, coxsackievirus-adenovirus receptor; CCl4, carbon
tetrachloride; CREBBP, CREB binding protein; CTGF, connective tissue growth
factor; DMN, dimethylnitrosamine; DOX, doxorubicin; ECM, extracellular matrix;
EMT, epithelial-to-mesenchymal transition; GFP, green ﬂuorescent protein;
HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; HSA, human
serum albumin; HSC(s), hepatic stellate cell(s); IFN-γ, interferon-γ; IL10,
interleukin-10; KC(s), Kupﬀer cell(s); LAP, latency-associated peptide; LOXL2,
lysyl oxidase like 2; LSEC(s), liver sinusoidal endothelial cell(s); M6P, mannose
6-phosphate; M6P/IGFII, mannose 6-phosphate/insulin-like growth factor II;
MFB(s), myoﬁbroblast(s), mim γ, IFN-γ peptidomimetic; miR, miRNA(s); MMP,
matrix metalloproteinase; MPA, mycophenolic acid; NGF, nerve growth factor;
MSCs, mesenchymal stem cells; NAFLD, non-alcoholic fatty liver disease; NASH,
non-alcoholic steatohepatitis; NT, neurotrophin; OM, Oxymatrine; p75NTR, p75
neurotrophin receptor; PDGF, platelet-derived growth factor; PDGFβR, PDGF
receptor type β; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic acid);
PPARγ, peroxisome proliferator-activated receptor γ; PPB, PDGFβR-recognizing
cyclic peptide; PTEN, phosphatase and tensin homolog; PTX, pentoxifylline; RBP,
retinol-binding protein; SSLs, sterically stable liposomes; TFO(s), triplex forming
oligonucleotide(s); TGF, transforming growth factor; TIMP, tissue inhibitor of
metalloproteinase; TNF, tumor necrosis factor; Trk, tropomyosin-related kinase;
TSP-1, thrombospondin-1.
including collagen type I and type III, the latter being central
to hepatic ﬁbrogenesis. In this scarring process, the altered non-
functional connective tissue replaces functional liver tissue. In
addition to their activation by cytokines, HSCs maintain and
even potentiate liver ﬁbrosis through the eﬀect of numerous
autocrine feedback loops, thereby substantially contributing to
the progression of the disease (Poelstra et al., 2012).
Similarly, portal ﬁbroblasts that are located in portal areas
are able to acquire an MFB-like phenotype and play a
particularly important role in biliary ﬁbrosis (Povero et al., 2010).
Furthermore, bone marrow-derived stem cells, such asMSCs and
circulating ﬁbrocytes, can diﬀerentiate into MFBs. The cellular
fraction of proﬁbrogenic cells is further increased by hepatocytes
and cholangiocytes that both have the capacity to lose their
epithelial phenotype and gene expression characteristics and
change into mesenchymal cells with the ability to form ECM
compounds. This concept of EMT has implicated PCs as direct
cellular sources contributing to matrix synthesis and ﬁbrogenesis
(Povero et al., 2010). Although EMT of cholangiocytes has been
conﬁrmed in the context of biliary ﬁbrosis, the actual quantity of
EMT of PCs in the development of liver ﬁbrosis is still a subject
of debate (Povero et al., 2010; Scholten and Weiskirchen, 2011).
These somewhat contradictory observations show that activated
ﬁbroblasts in the liver are a heterogenous pool of cells (Zeisberg
and Kalluri, 2013). As such, it is not surprising that the course
of ﬁbrotic disease can be so varied not only within the liver but
also diﬀer from that in other organs such as the lung, kidney,
and heart, despite the obvious macroscopic and microscopic
commonalities that they share. Indeed, several organ-speciﬁc
features of hepatic ﬁbrosis have been noted.While viral infections
trigger hepatic ﬁbrogenesis, infections are not a common cause
for ﬁbrosis in kidney, heart, and lung. Likewise, compared to all
other organs, the liver has by far the best regenerative capacity to
repair acute and chronic insults. In addition, the ﬁnal outcome
of ﬁbrosis in diﬀerent organs may diﬀer dramatically. The liver
is also unique with regards to the fact that advanced liver ﬁbrosis
can progress to cirrhosis and HCC (Gressner and Weiskirchen,
2006). In addition, there are several good serum markers for
measurement of hepatic ﬁbrosis, whereas biochemical blood tests
that correspond for example with heart ﬁbrosis are not available
(Zeisberg and Kalluri, 2013).
Fibrosis research in hepatology employs animal models in
order to detect relevant disease-promoting mechanisms and
to further translate these ﬁndings into the development of
antiﬁbrotic drugs. Currently, models using rodents are the gold
standard, because these models can reproduce or mimic any
human liver disease independent of its cause (Liedtke et al.,
2013).
At present, two models are most frequently used in
experimental ﬁbrosis (Iredale, 2007). The ﬁrst model employs
repetitive toxic damage such as that induced by CCl4. The
application of this hepatotoxin creates a model of postnecrotic
ﬁbrosis (Brenner, 2009). In contrast bile duct ligation, the second
model, simulates secondary biliary ﬁbrosis (Brenner, 2009).
Additional commonly used models include the use of special
diets such as the methionine choline deﬁcient diet which causes
a rapid micro- and macro-vesicular steatosis resulting in liver
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injury similar to human NASH as well as the administration
of heterologous serum, which mimics autoimmune hepatitis
(Brenner, 2009). These models have been used to highlight the
action of cytokine signaling pathways in liver ﬁbrosis.
Due to their crucial role in the activation of HSCs and
progression of hepatic ﬁbrosis, cytokines, cytokine receptors, and
cytokine-driven pathways oﬀer numerous attractive therapeutic
targets. Principally, there are three possibilities to target the
ﬁbrotic activities of cytokines. Firstly, a cytokine with a known
antiﬁbrotic activity can be delivered to speciﬁc target cells.
Secondly, the pro-ﬁbrogenic eﬀect of a cytokine can be blocked
by a potent inhibitor or antagonist at the site of ﬁbrosis, thus
developing an antiﬁbrotic eﬀect. And thirdly, cytokine receptors
on speciﬁc target cells can be used as docking sites for targeted
drug delivery, thereby ameliorating eﬃcacy and reducing adverse
drug reactions due to lower oﬀ-target eﬀects. In the following,
several examples that illustrate these three possibilities are
given.
CELL-SPECIFIC DELIVERY OF
CYTOKINES WITH AN ANTIFIBROTIC
ACTIVITY
Interleukin-10 is the prototype of an anti-inﬂammatory cytokine
that suppresses inﬂammatory reactions and can attenuate
excessive tissue scarring (Hammerich and Tacke, 2014). To
circumvent comprehensive eﬀects in other body regions and
to evade its speedy clearance by the kidney, one research
group linked IL10 to M6P-groups, which speciﬁcally bind to
the M6P/insulin-like growth factor II (M6P/IGFII) receptor
(Rachmawati et al., 2007). This receptor is predominantly
expressed on the surface of activated HSCs during the course
of liver ﬁbrosis (de Bleser et al., 1995). The study demonstrated
that the M6P-IL10 compound retained the anti-inﬂammatory
and antiﬁbrotic action typical of IL10, the latter indicated
by a reduction of collagen type I deposition in a CCl4-
induced rat model of experimental ﬁbrosis. As expected, M6P-
IL10 accumulated in rat livers. However, due to its negative
charge, M6P does not only bind to HSCs but also to the
scavenger receptor type A, which is present in KCs and
sinusoidal endothelial cells (LSECs). Therefore, the modiﬁcation
of IL10 via M6P should not be considered an HSC-speciﬁc
delivery, but rather a means to improve liver accumulation
and pharmacokinetics, thus creating a potential candidate for
therapeutic application.
Besides IL10, the cytokine IFN-γ also exhibits antiﬁbrotic
eﬀects. IFN-γ evidently blocks diﬀerent steps during the
activation of HSCs as well as the synthesis of ECM in ﬁbroblasts.
Furthermore, it can even reduce ﬁbrosis in certain patients
(Rockey, 2008). Since IFN-γ has extensive pro-inﬂammatory
properties, major problems arise in systemic therapy including
adverse reactions, such as ﬂu-like symptoms, generalized
activation of immune cells, hyperlipidemia, and provocation of
autoimmune reactions, and toxicity to the bone marrow and
induction of depression (Bansal et al., 2011). These side eﬀects
can occur due to the fact that IFN-γ receptors are present on
virtually every cell type in the body, which is likely why its
antiﬁbrotic activity is not as profound in vivo as it is in vitro.
To ameliorate the beneﬁts whilst at the same time minimizing
adverse eﬀects, it was proposed to directly deliver IFN-γ to
activated HSCs. Since the platelet-derived growth factor beta
receptor (PDGFβR) is abundantly found on the cell surface of
activated HSCs, ﬁrst a cyclic peptide speciﬁcally binding to this
receptor was constructed, displaying the amino acid sequence
∗CSRNLIDC∗ as a structural element (Beljaars et al., 2003; Bansal
et al., 2011). Next, this PDGFβR-recognizing cyclic peptide (PPB)
was linked to IFN-γ either directly or via a PEG bridge. Then,
the eﬀect of both compounds on HSCs and on ﬁbroblasts was
determined in vitro. Finally, an in vivo test followed employing
mice with CCl4-induced acute and chronic stages of liver damage.
Consistently, the variant containing the PEG linker (IFN-γ-PEG-
PPB) generated the most remarkable antiﬁbrotic activity: The
compound blocked both angiogenesis and hepatic inﬂammation
and even caused ﬁbrolysis in the advanced stage of hepatic
ﬁbrosis, while it also led to a decline of IFN-γ-associated adverse
reactions (Bansal et al., 2011).
Bansal et al. (2014a,b) and coworkers further reﬁned this
approach by developing a synthetic compound consisting of the
signaling portion of IFN-γ and lacking the binding site for the
IFN-γ receptor, termed mim γ, and a BiPPB, both linked via
heterobifunctional PEG adapter units. The resulting chimeric
structure (mim γ-BiPPB) could solely bind to the PDGFβR on
activated HSCs and considerably blocked CCl4-induced acute
and chronic stages of hepatic ﬁbrosis in mice as indicated by a
reduction of α-SMA, desmin, and collagen type I mRNA and
protein expression, while oﬀ-target eﬀects were not observed
(Bansal et al., 2014b).
TARGETED BLOCKING OF THE
PRO-FIBROGENIC EFFECT OF
CYTOKINES
Apart from PDGF, TGF-β1 is indeed the major pro-ﬁbrogenic
cytokine involved in hepatic ﬁbrosis, as it regulates the
production and deposition of ECM (Qi et al., 1999; Breitkopf
et al., 2005). Generally, there are diﬀerent ways for interfering
with TGF-β signaling: Firstly, TGF-β expression can be
down-regulated by applying anti-sense oligonucleotide mRNA,
secondly, a targeted blocking of a speciﬁc isoform of TGF-
β by means of monoclonal antibodies is feasible, thirdly, the
activation of TGF-β receptors can be inhibited by the use of
speciﬁc inhibitors, thereby halting downstream signaling, and
fourthly, the local activation of TGF-β induced by αvβ6 integrin
and by TSP-1 can be prevented (Hayashi and Sakai, 2012).
TISSUE-SPECIFIC BLOCKING OF THE
LOCAL ACTIVATION OF TGF-β
In an early study, it was established that the amino acid sequence
Leu-Ser-Lys-Leu (LSKL) naturally occurs in the region of the
amino terminus of the LAP and that it can hamper the activation
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of latent TGF-β by TSP-1 through competitive inhibition (Ribeiro
et al., 1999). The LAP, which forms a dimer with mature TGF-β,
is necessary for the transfer of TGF-β through the cell membrane
and hampers its receptor binding before activation (Hayashi and
Sakai, 2012).
To determine the inﬂuence of LSKL peptides on hepatic
ﬁbrogenesis, rats were treated with DMN for 4 weeks (Kondou
et al., 2003). DMN leads to liver atrophy and ﬁbrosis, but a
concomitant daily administration of LSKL peptides signiﬁcantly
reduced the amount of changes compared to that observed in
animals of control groups. Furthermore, the quantity of both
active TGF-β1 and phosphorylated Smad2 was lower in the
LSKL-treated group, indicating that LSKL blocks the activation of
TGF-β1 and as a consequence the entire signaling cascade, thus
avoiding the further progress of hepatic ﬁbrosis (Kondou et al.,
2003).
Later it was demonstrated that a loss of TSP-1 gives rise to
a decrease of TGF-β1/Smad signaling and an increase in the
proliferation of hepatocytes (Hayashi et al., 2012). Since TGF-
β1 strongly blocks the proliferation of hepatocytes in vivo and
also triggers their apoptosis, antagonizing TSP-1 down-regulates
local activation of TGF-β1, up-regulates the proliferation of
hepatocytes and thereby promotes liver regeneration (Hayashi
et al., 2012). In contrast to its antiﬁbrotic and regenerative
eﬀects in the liver, the lack of TSP-1 does not impact the
activation of TGF-β1 during ﬁbrogenesis in other tissues. In
thrombopoietin-induced myeloﬁbrosis as well as in bleomycin-
induced pulmonary ﬁbrosis a lack of TSP-1 does not impact
bioavailability of TGF-β and does not protect from ﬁbrosis
(Evrard et al., 2011; Ezzie et al., 2011). Therefore, the local
activation of TGF-β by TSP-1 seems to be tissue-speciﬁc (Hayashi
and Sakai, 2012), and blocking of TSP-1, for example with LSKL
peptides, and its resulting antiﬁbrotic eﬀect might be exclusively
relevant to the liver.
ADENOVIRUS-MEDIATED
TRANSDUCTION OF HSCs
In order to investigate the eﬀect of overexpression of PPARγ on
liver ﬁbrosis in mice, one research group employed an adenovirus
expressing PPARγ for transduction (Yu et al., 2010). PPARγ
is a nuclear hormone receptor primarily occurring in the liver
and in adipose tissue, which is known to regulate a multitude
of genes in adipocytes (Sugii and Evans, 2011; Zhang et al.,
2013). Beside endogenous fatty acids also thiazolidinediones (i.e.,
the glitazones), which are synthetic therapeutic agents for the
treatment of type 2 diabetes, are known ligands of PPARγ (Zhang
et al., 2013). With respect to hepatic ﬁbrosis, PPARγ plays a
central role in the activation of HSCs, as PPARγ expression alone
is enough to restore the quiescent phenotype in activated HSCs
(Hazra et al., 2004) and both activation and proliferation of HSCs
correspond to exhausted PPARγ expression (Zhang et al., 2013).
In mice, 2 weeks after adenoviral transduction the expression
of ﬁbrosis-associated genes markedly declined, and liver ﬁbrosis
resolved (Yu et al., 2010). Also the shift of activated HSCs to the
quiescent state induced by PPARγ expression was accompanied
by a sharp decline of proliferation and induction of cell cycle
arrest in the G0/G1 phase as well as a rise in cell death in vitro,
altogether leading to the conclusion that it is possible to reverse
ﬁbrosis by overexpression of PPARγ (Yu et al., 2010). In line,
rosiglitazone (Avandia, GlaxoSmithKline) – a thiazolidinedione –
could both reduce hepatic ﬁbrosis in mice by downregulation
of the protein expression of α-SMA, TGF-β1, and CTGF and
re-establish the expression of PPARγ (Nan et al., 2009). The
researchers concluded that PPARγ, induced by rosiglitazone,
blocks the activation of HSCs and eliminates the expression of
TGF-β1 and CTGF, thus improving liver ﬁbrosis (Nan et al.,
2009). In addition, M6P-HSA-based delivery of rosiglitazone
inhibited HSC activation and diminished ﬁbrosis in a rat model
of CCl4-based chronic liver injury (Patel et al., 2012). However,
in a large clinical trial in patients with NASH, administration of
pioglitazone for 96 weeks did not signiﬁcantly ameliorate hepatic
ﬁbrosis compared to placebo or a control treatment with high-
dose vitamin E (Sanyal et al., 2010). Possibly, clinical data from
this so called Pioglitazone vs Vitamin E vs Placebo for Treatment
of Non-Diabetic Patients with Non-alcoholic Steatohepatitis
(PIVENS)-trial highlight the importance of improved targeting
for PPARγ agonists.
LIPOSOME-MEDIATED DELIVERY OF
IFN-α1b TO ACTIVATED HSCs
A study published by Du et al. (2007) was aimed at designing
an improved drug carrier that speciﬁcally targets HSCs. In
preparation for the planned in vitro and in vivo experiments,
they changed a cyclic peptide already characterized earlier
(Marcelino and McDevitt, 1995) that had been shown to
speciﬁcally recognize and bind to a non-integrin collagen type
VI receptor expressed on HSCs and upregulated on activated
HSCs (Beljaars et al., 2000). The amino acid sequence of
the original cyclic peptide used by Beljaars et al. (2000) was
Cys-Gly-Arg-Gly-Asp-Ser-Pro-Cys or C∗GRGDSPC∗, where C∗
indicates the cysteine residues linked via a disulfo bond, thus
forming the ring. The modiﬁcation introduced by Du and his
group was the substitution of cysteine with lysine, resulting
in the sequence C∗GRGDSPK∗. This cyclic peptide, which
displayed a higher stability than the original one, was combined
with SSLs by means of the sulfhydryl group of the cysteine
residue. SSLs are liposomes chemically modiﬁed by attaching
lipid derivatives of PEG, thus sterically stabilizing them (Allen
et al., 1995). PEG also served as a spacer for the linkage of
the cyclic peptide with the Arg-Gly-Asp motif (cRGD). The
SSLs reached a diameter of around 100 nm and were long-
circulating, an important basis for drug delivery in vivo. The
experiments assessed the binding aﬃnity of the cRGD peptide
to the collagen type VI receptor on HSCs as well as determined
the eﬃciency of delivery of IFN-α1b in rats subjected to
surgical ligation of the bile duct (BDL), a common model for
cholestatic ﬁbrosis. It was shown that the cRGD peptide tended
to bind to activated HSCs instead of binding to hepatocytes,
that the amount of cRGD peptide-labeled liposomes (cRGD-
SSLs) in HSCs extracted from BDL rats was increased by 10-fold
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compared to the quantity of unlabeled SSLs, and that IFN-
α1b delivered in cRGD-SSLs caused a signiﬁcant reduction of
hepatic ﬁbrosis in BDL rats in comparison to BDL rats of the
control group or to the group of BDL rats injected with IFN-
α1b delivered in unlabeled SSLs (Du et al., 2007). Blocking the
proliferation of activated HSCs by boosting apoptosis, cutting
ECM synthesis, and shutting down the release of TGF-β are
counted among the pharmacological eﬀects of IFN-α, responsible
for the observed improvement of liver ﬁbrosis in BDL rats (Du
et al., 2007).
Taken together, this study was the ﬁrst successful delivery of
a drug to activated HSCs using liposomes as a carrier. cRGD-
SSLs speciﬁcally bind to activated HSCs and are incorporated
via receptor-mediated endocytosis, followed by the release of
the drug. Due to their binding speciﬁcity they might qualify for
targeted drug delivery to activated HSCs to improve antiﬁbrotic
therapy (Du et al., 2007). It should be noted that non-
functionalized liposomes, however, do not target HSCs. In mouse
models of hepatic ﬁbrosis, dexamethasone-loaded liposomes have
antiﬁbrotic eﬀects, but they primarily target hepatic macrophages
and T-lymphocytes (Bartneck et al., 2015).
LIPOSOME-MEDIATED DELIVERY OF
OXYMATRINE TO HSCs
Chai et al. (2012) also applied RGD peptide-labeled liposomes
for the speciﬁc delivery of OM in order to examine whether
this herbal medicinal product would have a beneﬁcial eﬀect on
CCl4-induced liver ﬁbrosis in rats. OM is a natural quinolizidine
alkaloid obtained from the roots of the Sophora alopecuraides
L. and other Sophora plants (Figure 1), which exhibits various
FIGURE 1 | Therapeutic potential of Oxymatrine in hepatic injury. (A,B)
Oxymatrine can be extracted from the roots of Sophora plants. Sophora
flavescens is an evergreen, slow growing, nitrogen fixing shrub that requires a
sunny site for growing. The flowers of this plant grow in simple inflorescences
that vary in color from white, yellow, orange, red, or purple. (C) Oxymatrine is
a heterocyclic quinolizidine alkaloid that has a variety of therapeutic activities
in the liver. Several of these activities that were identified in vitro or in animal
models are listed. The photos in (A,B) were kindly provided by Hiroshi
Moriyama (http://wildplantsshimane.jp).
pharmacological properties: It blocks the replication of the
hepatitis B virus (Chen et al., 2001; Wang et al., 2011)
and also stops liver ﬁbrosis (Chen et al., 2001). Besides
this antiviral eﬀect, OM additionally shows apoptosis-inducing
activity, predominantly observed in several cancer cell lines,
for example in human pancreatic cancer cells (Ling et al.,
2011) as well as in human hepatoma SMMC-7721 (Song et al.,
2006; Liu et al., 2015) and Hep-G2 cells (Liu et al., 2015). An
antiﬁbrotic eﬀect has been studied in rats with CCl4-induced
liver ﬁbrosis, since OM potently limits the production as well as
deposition of collagen, probably by upregulation of SMAD7 and
downregulation of SMAD3 and CREBBP (CREB binding protein)
gene expression, thus interfering with the canonical TGF-β1
signaling pathway (Wu et al., 2008). Before conducting their
experiments, the researchers formed the OM-liposomes using
lipids and the OM-containing aqueous solution and afterward
coupled the RGD peptides and the OM-liposomes. Then OM-
RGD-liposomes, OM-liposomes, and empty liposomes were
allocated to three diﬀerent groups of rats, while a fourth
group of rats remained untreated. Liver ﬁbrosis improved upon
administration of OM, as assessed by reduced deposition of
collagen and reduced expression of genes co-occurring with liver
ﬁbrosis, such as MMP-2, TIMP-1, and type I procollagen (Chai
et al., 2012). In vitro, apoptosis of HSCs was induced by OM-
RGD-liposomes and gene expression of MMP2, TIMP1, and
COL1A2 was inhibited. Furthermore, RGD labeling improved
binding to HSCs (Chai et al., 2012).
In sum, OM improved CCl4-induced liver ﬁbrosis in rats by
restricting the viability of HSCs and by inducing their apoptosis.
Additionally, labeling of liposomes with RGD peptides intensiﬁed
binding to HSCs, thereby boosting the therapeutic beneﬁt (Chai
et al., 2012).
LIPOSOME-MEDIATED TRANSDUCTION
OF HSCs
While most groups attempted to target HSCs and to deliver
antiﬁbrotic agents in pursuit of the goal of impairing TGF-β1-
inducred collagen deposition or of eliminating activated HSCs
(Adrian et al., 2007a; Sato et al., 2008; Chai et al., 2012), Narmada
and coworkers, instead, focused on deploying the capacities
inherent in HSCs in order to trigger liver regeneration. To that
end the research group examined the antiﬁbrotic eﬀects of HGF
production induced in HSCs (Narmada et al., 2013).
Throughout the development and diﬀerentiation of the liver in
rats, HGF ismainly produced in HSCs and LSECs (Hu et al., 1993;
Nakamura et al., 2011; Mogler et al., 2015). Among the various
other physiological functions of HGF, suppression of apoptosis
might be the most notable feature: In mice, HGF was shown
to block apoptosis of hepatocytes, thus circumventing hepatic
failure (Kosai et al., 1999). Contrary to this observed boost of
hepatocyte survival, HGF inhibited proliferation and furthered
apoptosis of α-SMA-expressing portal MFBs and activated HSCs,
accompanied by resolution of cirrhosis, which was attributed to
the expression of the c-Met receptor in both liver cell types (Kim
et al., 2005). Furthermore, HGF countered TGF-β1-mediated
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production of collagen type III and α-SMA in ﬁbroblasts (Jiang
et al., 2008) and also decreased TGF-β1-induced expression of
CTGF in ﬁbroblasts in the kidney, thereby blocking synthesis of
α1(I) procollagen (Inoue et al., 2003). Besides antagonizing TGF-
β1-induced collagen deposition, an additional antiﬁbrotic eﬀect
arises from its ability to trigger the expression of proteases which
participate in the degradation of the ECM, including MMP-9
(Nakamura et al., 2011),MMP-3, andMMP-13 (Kanemura et al.,
2008). And in addition to boosting proliferation of hepatocytes
(Nakamura, 1994), HGF strengthened proliferation as well as
migration of diﬀerent cell types, including endothelial (Morimoto
et al., 1991) and mesothelial cells (Warn et al., 2001), but in
multiple cancer cell lines, such as in hepatoma HepG2 cells, HGF
exerted a potent antiproliferative eﬀect, thus obviously displaying
bidirectional impacts (Tajima et al., 1991).
To target HSCs, Narmada et al. used vitamin A-coupled
liposomes surrounding the HGF transgene. To that end, the
researchers had to produce a plasmid containing the HGF gene,
referred to as the pDsRed2-HGF plasmid. After coating of the
liposomes with vitamin A, the plasmid DNA was inserted into
the vitamin A-liposomes, resulting in vectors with the size of
approximately 600 nm (Narmada et al., 2013). The use of vitamin
A-coated liposomes as carriers addressed the ability of HSCs to
take up and store vitamin A, which is why HSCs are also termed
vitamin A-storing cells (Senoo et al., 2007) and the coating
procedure was analogous to the one described earlier (Sato et al.,
2008). It is hypothesized that vitamin A-uptake by HSCs depends
on RBP and that, after forming of the vitamin A-RBP-complex,
speciﬁc receptors occurring on HSCs then bind the RBP-subunit
and incorporate the complex via receptor-mediated endocytosis
(Senoo et al., 2007). But there is also evidence that RBP may
not be essential for the uptake of vitamin A by HSCs: It was
shown that hepatic vitamin A levels in RBP-deﬁcient and in wild-
type mice did not diﬀer signiﬁcantly, leading to the conclusion
that a lack of RBP does not aﬀect the uptake of vitamin A in
the liver (Quadro et al., 1999). Moreover, vitamin A storage is
not involved in proﬁbrogenic functions of HSC per se (Kluwe
et al., 2011). In their study Sato and colleagues could verify that
vitamin A-coupled liposomes speciﬁcally target HSCs and stated
that uptake via speciﬁc receptors for RBP would be most likely
(Sato et al., 2008).
To prove the antiﬁbrotic eﬀects of vitamin-A-liposomes
comprising the pDsRed2-HGF plasmid, Narmada et al. (2013)
conducted in vitro investigations using a cell culture of the
rat stellate cell line HSC-T6 as well as a co-culture of HSC-
T6 and hepatocytes, and additionally administered the liposome
formulation to rats suﬀering fromDMN-induced hepatic ﬁbrosis.
In vitro experiments showed that the modiﬁed liposomes were
capable of down-regulating ﬁbrotic factors (Narmada et al.,
2013). Fibrotic rats only once treated with a plasmid-containing
liposomes by means of retrograde intrabiliary infusion exhibited
a rise of HGF gene expression and a simultaneous reduction
of the ﬁbrotic markers α-SMA, TGF-β1, and collagen type
I, resulting in regression of hepatic ﬁbrosis (Narmada et al.,
2013).
Taken together, targeting pDsRed2-HGF plasmid-containing
vitamin A-liposomes to HSCs entailed raised HGF gene
expression and a decline in ﬁbrosis-speciﬁc marker proteins and
could possibly be optimized to cure liver ﬁbrosis with the help of
gene therapy.
THERAPEUTIC NANOPARTICLES
Strictly taken, nanoparticles are sized from one up to 10 nm,
however, the deﬁnition is frequently being extended to the sub-
micron range up to 500 nm (Zhang et al., 2008). Principally, one
can distinguish organic and inorganic nano-sized particulates.
Gold nanoparticles are probably the most frequently used
inorganic nanoparticles and are popular due to the ease of
tailoring size, shape, and functionalization (Bartneck et al.,
2010). Metal-based nanotherapeutics oﬀer optical and magnetic
properties, which allow their usage in imaging techniques such
as computerized tomography (Bartneck et al., 2012). On the
downside, inorganic carriers accumulate in the body since
they are not biodegradable (Bartneck et al., 2012). Organic
nanoparticles such as lipid or polymer-based constructs exhibit
the advantage that many of them are biodegradable and therefore
should be considered as clinically relevant nanocarriers.
Irrespective of the particle nature, its size and
functionalization determine the distribution in diﬀerent organs.
Generally, particles or constructs sizing above 10 nm translocate
to liver and spleen and only minor amounts enter the kidney,
whereas those below 10 nm were shown to also enter kidney,
testis, and brain (Nikoobakht et al., 2002). Nanotechnological
modiﬁcations oﬀer particle engulfment with compounds that
also aﬀect the physicochemical properties of the construct. PEG
is among the most popular modiﬁcations to modify particle
properties (Bartneck et al., 2010). The PEG-induced reduction of
unspeciﬁc interactions with proteins also reduced uptake by liver
phagocytes due to the resulting neutral particle charge (Bilzer
et al., 2006).
TARGETED DELIVERY OF THERAPEUTIC
AGENTS WITH THE HELP OF A
CYTOKINE RECEPTOR
Similar to the chemical modiﬁcation of cytokines, such as IL10
and IFNγ, to enable their binding to speciﬁc receptors on
predeﬁned target cells, drugs can be linked to speciﬁc carriers,
allowing them to bind to cytokine receptors on target cells. With
regard to liver ﬁbrosis, the activated HSC constitutes the target
cell of choice, and several eﬀorts were carried out to selectively
deliver drugs with an antiﬁbrotic eﬀect to activated HSCs in
experimentally induced liver ﬁbrosis.
TARGETING THE M6P/IGF-II RECEPTOR
ON ACTIVATED HSCs
The most frequently used receptor is the M6P/IGF-II receptor,
which is a transmembrane glycoprotein with a wide range
of regulatory functions. Due to its structure, it can act as a
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clearance receptor, leading to degradation of proteins through
endocytosis and as a signaling receptor engaged in G-protein
dependent signal transduction (El-Shewy and Luttrell, 2009;
Heger and Schlüter, 2013). Based on the large extracellular
portion of the M6P/IGF-II receptor, binding of many diﬀerent
ligands is possible: Both interactions with M6P-containing
ligands, such as renin, latent TGF-β1, thyroglobulin, proliferin,
leukemia inhibitory factor, and granzyme B, and recognition of
M6P-free ligands, for example IGF-II, retinoic acid, urokinase-
type plasminogen activator receptor, and plasminogen are
well documented (Heger and Schlüter, 2013). The cytoplasmic
domain does not display any catalytic activity, so after ligand
binding the receptor shuttles between the cell membrane and
intracellular compartments, such as lysosomes (El-Shewy and
Luttrell, 2009; Heger and Schlüter, 2013).
The ﬁrst step on the path to targeted delivery was made
by Beljaars et al. (1999), when they developed and tested
a carrier, designed to speciﬁcally bind to the M6P/IGF-II
receptor on activated HSCs. This receptor is strongly activated
during transdiﬀerention of HSC and is closely associated with
expression of α-SMA and the pathophysiology of liver disease
(Trim et al., 2000; Cassiman et al., 2001). For example, it
is strongly upregulated in HSC during hepatic carcinogenesis
(Figure 2).
The mentioned carrier consisted of HSA, to which M6P
groups had been added: Four diﬀerent constructs with an
increasing amount of M6P groups, i.e., with a molar ratio of
M6P:HSA amounting to 2:1, 4:1, 10:1, and 28:1, were generated
(Beljaars et al., 1999). First, the accumulation of the compounds
in ﬁbrotic livers of rats was determined: the uptake rose with an
increasing degree of substitution (Figure 3). Compounds with a
molar ratio less than or equal to 10:1 accumulated only at rates
of 9% ± 5% or less in the liver, whereas a ratio of 28:1 led to
a jump to 59% ± 9% of the originally delivered dose (Beljaars
et al., 1999). Next, the accumulation in HSCs was ascertained
employing double-immunostaining techniques, i.e., for HSA and
HSCs: Here, too, the uptake of M6P-HSA rose with an increasing
degree of substitution and 70%± 11% of the intrahepatic staining
for the conjugate with a 28:1 ratio was located in HSCs (Beljaars
et al., 1999). In addition, it could also be shown that BSA linked
to M6P massed in human non-PCs of the liver (Beljaars et al.,
1999). The authors concluded that M6P-albumins could function
as selective drug carriers to HSCs.
Since then, the M6P-HSA carrier has been used more
often for the delivery of antiﬁbrotic drugs to HSCs. The
immunosuppressive drug MPA, which is capable of blocking
proliferation of ﬁbroblasts, was coupled to M6P-HSA, intending
to avoid immunosuppression and to improve its antiﬁbrotic
FIGURE 2 | The neutrotrophin receptor as a therapeutic target. (A) The tyrosine kinase NGFR p75 is significantly upregulated in HSCs during cancerogenesis.
In this experiment, the expression of NGFR p75 was analyzed by Western blot in human specimens derived from non-tumor and tumor areas of HCC patients. The
analysis revealed a strong upregulation of NGFRp75 in diseased liver areas. The following antibodies were used in this set of experiments: NGFR p75 (sc-6188,
Santa Cruz Biotech, Santa Cruz, CA, USA), α-SMA (CBL171, Cymbus Biotech, Hampshire, UK), glial fibrilliary acidic protein (GFAP, sc-6170, Santa Cruz), β-actin
(A5441, Sigma, Taufkirchen, Germany). The membrane was counterstained with Ponceau S to document equal gel loading. The striking difference in protein content
in sample “patient 8” was due to extremely high bilirubin content in this probe. (B) Immunhistochemical analysis of NGFR p75 and α-SMA expression in human
samples obtained from normal and tumorigenic liver samples. Please note the strong expression of NGFR p75 in cells that were stained positive for α-SMA that
becomes visible in the merged images. Cells were counterstained with DAPI. Magnifications were 100x (upper two panels) or 200x (lower two panels). The usage of
human samples is covered by an ethical vote from the relevant authority (Institutional Review Board of the Bonn University Ethics Committee, decision #067/10). The
results depicted in this figure are similar to a variety of previous studies that have already shown that NGFR p75 is expressed by HSC and strongly upregulated
during transdifferentiation (Trim et al., 2000; Cassiman et al., 2001; Asai et al., 2006; Passino et al., 2007; Kendall et al., 2009; Zvibel et al., 2010; Reetz et al., 2013;
Patil et al., 2014).
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FIGURE 3 | Targeting the M6P/IGF-II receptor by M6P coupling. The coupling of substances to mannose-6-phosphate (M6P) is an effective means to increase
the activity of the M6P/IGF-II receptor. The coupling of human serum albumin resulted in improved pharmacokinetics and affinity for the M6P/IGF-II receptor. This
receptor is significantly increased in profibrogenic cells expressing α-SMA. High MP6:HSA coupling ratios resulted in increased hepatic accumulation (Beljaars et al.,
1999). This concept of M6P coupling was also successfully tested for IL10 (Rachmawati et al., 2007). The structures of human IL10 and HSCs were generated using
the entries 2H24 and 1E7I that are deposited in the RCSB Protein Data Bank and the Ribbons XP software. The space bars each represent 10A. Details about the
crystal structures of human IL10 and HSA are provided elsewhere (Bhattacharya et al., 2000; Yoon et al., 2006).
activity (Greupink et al., 2005). Speciﬁc binding of the conjugate
to HSCs and a reduction of their proliferation could be observed
in vitro. In vivo, it selectively accumulates in the liver – primarily
in HSCs and also in KCs and LSECs, but not in primary and
secondary lymphoid tissues (Greupink et al., 2005). Furthermore,
in BDL treated rats the compound minimized liver inﬂammation
and, likewise, the mRNA expression of α-β-Crystallin, which
functions as a marker for the activation of HSCs (Greupink et al.,
2005). In summary, coupling of MPA to the M6P-HSA carrier
and subsequent targeted delivery led to a decline of the activation
of HSCs.
Using the same carrier, the antiﬁbrotic drugs PTX, a drug that
has an antiproliferative eﬀect on HSCs and blocks their activation
in vitro (Gonzalo et al., 2006), DOX, which also potently impairs
proliferation of HSCs in vitro (Greupink et al., 2006), 15-deoxy-
12,14-prostaglandin J2 (15dPGJ2), an apoptosis-inducing
drug (Hagens et al., 2007), as well as 4-chloro-N-[4-methyl-
3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
(PAP19), a tyrosine kinase inhibitor and a derivative of
imatinib (Gonzalo et al., 2007) and 18β-glycyrrhetinic acid
(18β-GA) also known as enoxolone (Luk et al., 2007) could
all be successfully delivered to HSCs to selectively unfold their
respective activity.
Another research group applied a M6P-BSA carrier in a
slightly diﬀerent form: The researchers coupled TFOs and M6P-
BSAwith the help of disulﬁde bonds (Ye et al., 2005). TFOs can be
used for gene silencing through triplex formation with genomic
DNA, i.e., promoter sequences, thereby inhibiting transcription
of the genes concerned. To optimize the uptake of M6P-BSA-
TFO by the liver, based on prior testing a conjugate with a
molar ratio of M6P:BSA equal to 20:1 was chosen. It could be
determined that nearly 66% of the administered conjugate had
accumulated in the liver of rats 30min following its injection, and
a high amount of the delivered dose could be detected in HSCs,
thus suggesting its use for the therapy of liver ﬁbrosis (Ye et al.,
2005).
Adrian et al. (2007b) described the coupling of M6P-HSA
to liposomes with the aim to ascertain the pharmacokinetics
of M6P-HSA-liposomes and their speciﬁcity to target HSCs.
Liposomes constitute artiﬁcial globular entities with one or
more phospholipid bilayers forming an envelope around an
aqueous core (Giannitrapani et al., 2014; Neophytou and
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Constantinou, 2015) and are capable of carrying both hydrophilic
and lipophilic agents: Hydrophilic drugs are placed within the
aqueous core whereas lipophilic molecules are integrated into
the phospholipid bilayer. Being counted among the organic
nanoparticles, liposomes feature several advantages: Beyond
their solid biocompatibility they can be easily produced, exhibit
only minor systemic toxicity, and are quickly eliminated from
the blood and taken up by the reticuloendothelial system
(Giannitrapani et al., 2014). In preparation for their study,
the researchers added 29 M6P groups on average to each
albumin molecule and, in a second step, about 31 M6P-HSA
molecules on average were linked to one liposome. The resulting
M6P-HSA-liposomes had a size of roughly 100 nm. BDL-
treated rats were employed to perform the following in vivo
experiments: Radioactively labeled M6P-HSA-liposomes was
injected intravenously, and both their elimination from the
blood as well as their distribution were monitored. Ten minutes
following injection, 90% of the original dose of 3[H]-M6P-HSA-
liposomes was removed from the blood and predominantly
aggregated in the liver (Adrian et al., 2007b). Apart from
HSCsM6P-HSA-liposomes also concentrated in KCs and LSECs,
and accumulation in the last two cell types could be blocked
by previously administered polyinosinic acid, which acts as a
competitive inhibitor of scavenger receptors class A, indicating
that this receptor type is responsible for the recognition of
M6P-HSA by KCs and LSECs and not by HSCs (Adrian et al.,
2007b). Furthermore, injection of uncombined M6P-HSA prior
to the administration of M6P-HSA-liposomes resulted in a
decreased liver uptake of 15% accompanied by an increase
of accumulation in the lungs, due to an extended presence
in the blood circulation and probably binding to pulmonary
intravascular macrophages within the injured lungs of BDL
rats.
In previous studies (Pereira Paz, 2004; Benner, 2007),
we in cooperation with other groups have established novel
biodegradable M6P-coupled PLGA nanoparticles that have a
porous structure allowing to be dotted with various substances
(Figure 4). Based on the ﬁnding that the IGF-II/M6P receptor
is found to be strongly upregulated during transdiﬀerentiation,
we tested if these vehicles can be targeted into the liver.
Therefore, we dotted these nanoparticles with barium sulfate that
acts as a radiopaque contrast media and found that respective
FIGURE 4 | Mannose-6-Phosphate coating of nanoparticles for targeted delivery of pharmacological active compounds to activated HSCs and
MFBs. (A) Several reports have shown that the expression of the IGF-II/M6P receptor is strongly upregulated during transdifferentiation of quiescent HSCs to MFBs.
(B) Western blot analysis of cellular protein extracts of rat HSCs and rat MFBs that were cultured for indicated time intervals. The blot was probed with a
goat-anti-IGFIIR (sc-14413, Santa Cruz Biotechnology, Santa Cruz, CA, USA). (C) In a former study, we have generated biocompatible nanoparticles that are based
on PLGA and coated with M6P via flexible linkers. (D) These biodegradable particles have a porous container structure allowing to pack up (“dotting”) various
compounds into the cavities. (E) Respective nanoparticles were dotted with barium sulfate and injected into the tail vein of a rat. The radiography, that was prepared
approximately 2 h later, shows that these particles were enriched in the liver. More details about the production of the modified PLGA particles used in this study can
be found elsewhere (Pereira Paz, 2004).
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nanoparticles were enriched in the liver when applied via
the tail vein (cf. Figure 4). Unfortunately, in our hands the
synthesized particles caused a serious pulmonary embolism that
prevented further exploration of these biodegradable vehicles.
In addition, when we tested their speciﬁcity in vitro, we found
that respective FITC-dextran-loaded particles were taken up
not only by HSCs but also by ECs and hepatocytes and
highly eﬀective by KCs (Figure 5A). This ﬁnding was more
or less independent from their surface loading with M6P
(not shown), possibly indicating the exceptional scavenging
ability of the cells. Likewise, the application of FITC-dextran-
loaded nanospheres in vivo resulted in a strong uptake of the
respective particles not only in the liver but also in the spleen
(Figure 5B).
In sum, M6P-HSA-liposomes might be suitable to speciﬁcally
deliver drugs to HSCs, LSECs and KCs, and bothM6P/IGF-II and
scavenger receptors have the ability to detect and bind the M6P-
HSA subunit (Adrian et al., 2007b).
TARGETING THE p75 NEUROTROPHIN
RECEPTOR ON HSCs
Aiming at developing an eﬀective strategy to speciﬁcally target
HSCs using a gene delivery vector, Reetz et al. (2013) modiﬁed
the Ad serotype 5 envelope by two frequently used strategies
for in vivo targeting and evaluated the transduction eﬃciency of
both procedures. Since the wild-type Ad is capable of infecting
a wide spectrum of diﬀerent cell types in the liver, such as
hepatocytes, KCs and HSCs, its application for cell-speciﬁc
infection is challenging. This ubiquitous tropism is caused by the
modality of viral entry into the cell. First, Ad ﬁber knobs interact
with receptors on the surface of a host cell, particularly with the
CAR, thereby attaching the virus to the cell surface, followed by
a further interaction of the virus-CAR-complex with other co-
receptors, as for instance various integrins (Sharma et al., 2009;
Reetz et al., 2013). An RGD amino acid sequence within the
penton base, i.e., the coat protein of the Ad, is responsible for
FIGURE 5 | Limitation of the M6P targeting strategy. (A) Primary isolated KC, endothelial cells (EC), HSCs, and hepatocytes (parenchymal cells, PC) were
incubated with FITC-dextran-doted M6P-coated nanospheres. After 24 h, excess nanospheres were removed by washing two times with phosphate-buffered saline.
The growth medium was renewed and cells further incubated for another 24 h period. Then the cells were fixed in 4% paraformaldehyde and the cellular actin was
stained with a phalloidin-rhodamine complex. After a further wash step, the cells were fixed in Moviol (Merck Biosciences, Bad Soden, Germany) and analyzed by
confocal microscopy. (B) FITC-dextran doted nanospheres were injected via the tail vein into a stunned rat. 24 h later, the animal was sacrificed and organ specimen
derived from the central or peripheral area of the liver as well as from the spleen analyzed by light microscopy (left panels) and fluorescence microscopy (right
panels). Please note the high concentration of nanospheres (green beads) within the spleen. More details about this set of experiments can be found elsewhere
(Benner, 2007).
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binding to the vitronectin receptors αvβ3 and αvβ5, whereupon
via integrin-mediated signaling the internalization of the Ad
is eﬀected by means of receptor-ediated endocytosis (Wickham
et al., 1995; Sharma et al., 2009). Since the virus-CAR interaction
features high aﬃnity in contrast to the rather low aﬃnity of the
virus-integrin interaction, the former is critical for the eﬃciency
of infection and the tissue-speciﬁc occurrence of the CAR is
one of the key factors which determine adenoviral tropism
(Sharma et al., 2009). In consequence, to restrict the natural
tropism of the Ad it is necessary to sidestep binding of the virus
to the primary receptor and, instead, redirect the virion to a
receptor solely expressed on the target cell, which should be
genetically modiﬁed. To put this approach into practice Reetz
et al. (2013) developed a peptide (NGFP) derived from the
NGF and speciﬁcally binding to the p75 NT receptor (p75NTR)
expressed on HSCs. Being part of the TNF superfamily, p75NTR
is structurally characterized by a cysteine repeat motif, which
acts as a ligand binding domain and a cytoplasmic portion
called the death domain (Casaccia-Bonneﬁl et al., 1999). Ligands
of p75NTR are the NTs with NGF as prototype (Roux and
Barker, 2002), as well as BDNF, NT-3, and NT-4, which are
relevant for the development of the nervous system in vertebrates
(Lee et al., 2001). Additionally, NTs can also initiate signaling
by binding to Trk receptors with tyrosine kinase activity and,
depending on the participating receptors, signal response can
vary. If both p75NTR and Trk-A are stimulated, cell survival will
be triggered, whereas exclusive interaction with p75NTR induces
cellular death (Trim et al., 2000; Roux and Barker, 2002). The
FIGURE 6 | Modification of the natural adenoviral tropism employing two different approaches resulted in the specific targeting of the p75NTR
on HSCs. (A) The p75NTR-binding peptide NGFP and the wild-type Ad.GFP were covalently joined using PEGylation, thus forming Ad.GFP-PEG-NGFP (left)
as well as merged with the help of S11 adapter molecules, resulting in Ad.GFP-S11-NGFP (right). The single chemical bonds of PEG and viral proteins are
close together, thereby concealing both fiber knobs and RGD sequences on the viral surface, whereas the S11 fragment only binds to the fiber knobs,
keeping the RGD sequences free for integrin interaction. Since fiber knobs are blocked in either case, binding to CAR, for example on hepatocytes, is
inhibited and exclusive interaction of NGFP with p75NTR on the surface of HSCs can occur. (B) Wild-type Ad.GFP vectors can transduce hepatocytes,
Kupffer cells, and HSCs in the liver, identifiable by the green fluorescence of GFP (top). As a result of the viral modifications, both Ad.GFP-PEG-NGFP
(middle) and Ad.GFP-S11-NGFP (below) exclusively bound to and transfected quiescent and activated HSCs, but Ad.GFP-S11-NGFP showed an enhanced
transduction efficiency concerning activated HSCs (below).
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fact that p75NTR is expressed by HSCs and that NGF-binding
to p75NTR induces apoptosis of activated HSCs suggested that
stimulation of p75NTR could selectively target and eliminate
HSCs (Trim et al., 2000).
More than a decade later, Reetz et al. (2013) employed this
concept to demonstrate the adenovirus-mediated transfection
of HSCs for the ﬁrst time. In their experiments, the researchers
employed a wild-type Ad serotype 5 (Ad.GFP) as the vector,
transferring the GFP gene and retaining the adenoviral
natural tropism (Figure 6). The synthetic NGFP, composed
of amino acids 25–36 of the original NGF protein and exactly
corresponding to the portion of NGF necessary for binding
to p75NTR, was then coupled to Ad.GFP using two diﬀerent
techniques in order to vary the viral tropism: A single chain
antibody fragment (S11), speciﬁcally recognizing the Ad ﬁber
knobs as well as NGFP, served as an adapter molecule to form
Ad.GFP-S11-NGFP. Furthermore, NGFP and Ad.GFP were
covalently joined by means of polyethylene glycol – a procedure
termed PEGylation – thus building Ad.GFP-PEG-NGFP.
Subsequently, both derivatives were tested in vitro and in vivo,
allowing determining the eﬃciency of transfection based on
the level of green ﬂuorescence. Additionally, in healthy and
in BDL-treated mice HSCs were detected on the basis of their
ultraviolet vitamin A-ﬂuorescence, as recorded by intravital
FIGURE 7 | Cellular structures for targeting HSCs with nanoconjugate ligands. There are diverse different structures on HSCs, which have been used
earlier for targeted delivery. The targeted structures (list on the left side), the corresponding ligands (right side list), and their location on HSCs are depicted
in the scheme.
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ﬂuorescence microscopy. Data demonstrated that usage of
both Ad.GFP-S11-NGFP and Ad.GFP-PEG-NGFP restricted
liver tropism characteristic of the wild-type Ad, enlarged
transfection of HSCs, and both vectors equally displayed higher
transduction eﬃciency in ﬁbrotic liver versus healthy organs,
but – compared with Ad.GFP-PEG-NGFP – Ad.GFP-S11-NGFP
showed a higher targeting eﬃciency of activated HSCs (Reetz
et al., 2013).
In conclusion, targeting of p75NTR on HSCs with the use of
a modiﬁed adenoviral carrier could constitute a practicable and
powerful way of applying gene therapy to activated HSCs (Reetz
et al., 2013).
TARGETING PDGF AND THE RBP
RECEPTORS ON HSCs
PDGF is the most mitogenic factor that leads to increased
HSC proliferation in liver ﬁbrosis. PDGFRβ, which is one
of its two receptors, is critically upregulated on activated
HSCs (Bonner, 2004). Encouraging studies revealed a sterically-
stabilized liposome (SSL) equipped with the cyclic peptide
“C∗SRNLIDC∗ (pPB) with strong binding activity for the PDGF-
β receptor (and loaded with IFN-γ) enhanced anti-ﬁbrotic eﬀects
of IFN-γ in a murine model of TAA-based hepatic ﬁbrosis (Li
et al., 2012).
The retinol binding protein receptor which is involved in
storing retinol is another putative structure for targeting HSCs.
Hence, lipid-encapsulated and retinol-decorated siRNA versus
heat-shock protein 47, a collagen-speciﬁc chaperone, was shown
to ameliorate ﬁbrosis in diverse experimental mousemodels (Sato
et al., 2008). Nanoconjugate siRNA against TGF-β1 equipped
with an N-acetylglucosamin targeting moiety intending to reach
HSCs via desmin was reported to colocalize with HSCs and to
reduce ﬁbrosis (Kim et al., 2013). Due to the cytosolic presence
of desmin, the conjugates may also enter the cells via alternative
routes. Recently, siRNA directed against the procollagen α1(I)
gene has been deployed using cationic nanoparticles, leading
to an amelioration of ﬁbrosis. However, despite the therapeutic
success in preclinical studies, the delivery route was rather
unspeciﬁc and probably occurs through endocytosis since none
of the known cell-targeting motifs were used (Jiménez Calvente
et al., 2015) (Figure 7).
TRANSCRIPTIONAL TARGETING
APPROACHES FOR ACTIVATED
HSCs/MFBs
Comparative mRNA and protein expression analyses
demonstrated that HSCs have a characteristic and unique
gene signature that is signiﬁcantly modulated during the
transdiﬀerentiation into MFBs (Kristensen et al., 2000; Ji et al.,
2012; Azimifar et al., 2014; Zhang et al., 2015). Therefore, it was
assumed that several of these genes might be attractive targets for
tracking, targeting and cell isolation (Zhang et al., 2015). There
is a growing list of genes that are either expressed preferentially
in HSCs (within the liver) or become signiﬁcantly upregulated
in response to cellular activation and transdiﬀerentiation.
The group of “transdiﬀerentiation-sensitive genes” include
transcription factors, ECM proteins, cell adhesion molecules,
smooth muscle speciﬁc genes, cytokine receptors, and genes
encoding proteins involved in matrix remodeling, or cytoskeletal
organization (Table 1).
The identiﬁcation of factors and cis- or trans-acting
elements within such genes that trigger preferred expression
in HSCs/MFBs oﬀer important therapeutic opportunities.
Such regulatory elements could be exploited to express
antiﬁbrotic or apoptosis-associated transgenes speciﬁcally in
physiologically alteredHSCs, thereby inducing targeted clearance
of reprogrammed, activated HSCs/MFBs or preventing hepatic
expression of excessive ECM constituents. Several years ago, we
have shown in culture-activated HSCs that promoter fragments
of the CSRP2 and SM22α genes that are expressed exclusively
in the liver in HSCs are suﬃcient to mediate reporter gene
expression (Herrmann et al., 2004). Similarly, we found that
stretches taken from the transdiﬀerentiation-sensitive TIMP-1
promoter were able to achieve transgene expression in culture-
activated HSCs but not in cultured hepatocytes (Herrmann et al.,
2004). In a similar targeted gene transcription approach it was
shown that a 2.2-kbp fragment derived from the human GFAP
gene promoter was not only capable of directing HSC-speciﬁc
expression in vitro, but also conferred dose- and time-dependent
sensitivity to TGF-β that is the major cytokine responsible for
ECM formation (Maubach et al., 2006).
In another investigation, the GFAP promoter was fused to
the herpes simplex virus thymidine kinase gene. This transgene
was able to render susceptibility for ganciclovir-induced cell
death, both in in vitro and in vivo (Puche et al., 2013).
However, the usage of the GFAP promoter as a regulatory
element to drive transgene expression in activated HSCs or
transdiﬀerentiated MFBs is potentially hindered by the ﬁnding
that HSCs downregulate expression of GFAP and that this
gene is also signiﬁcantly expressed in neuronal tissues and
cholangiocytes (Yang et al., 2008). A similar ﬁnding was noticed
for the vimentin promoter that is predominantly active in
activated HSCs and MFBs in the liver, but is also eﬀectively
transcribed in vascular smooth muscle cells and portal ﬁbroblasts
(Troeger et al., 2012).
Unfortunately, the partial cellular selectivity of other
promoters that we observed in vitro was not found in vivo
emphasizing the complexity of regulatory factors that are
necessary to guarantee speciﬁc expression in HSCs (Herrmann
et al., 2004). In addition, the detailed analysis of α-SMA and
collagen I gene transcriptional patterns in primary cultures of
HSCs and in an in vivo model of secondary biliary ﬁbrosis by
means of transgenic mice that express the red ﬂuorescent protein
and the enhanced GFP under transcriptional control of respective
promoter elements revealed that these two genes were not co-
expressed in all cells (Magness et al., 2004). These data indicate
that HSCs are a fraction of cells that show heterogeneity during
hepatic insult, thereby potentially hampering and restricting
target approaches that use “HSC-speciﬁc” or promoters that
become activated during hepatic insult.
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miRNA-BASED STRATEGIES FOR HSC
TARGETING
Micro-RNAs (miR) are small but powerful molecules, which
usually size around 20 nucleotides and aﬀect the regulation
of mRNA (Lam et al., 2015). miR act by binding to the 3′
untranslated region (3′ UTR) of the target mRNA (Lam et al.,
2015). Since the complementarity of miR-to-mRNA sequence is
only partial, the miR can bind to multiple diﬀerent mRNAs (Lam
et al., 2015). Bioinformatics-based predictions have led to the
assumption that about 60% of protein coding genes are regulated
by miR (Friedman et al., 2009). Many diﬀerent miR are involved
in inﬂammatory diseases (Roy et al., 2015). Inﬂammation
is considered the main initiating event in ﬁbrogenesis and
an important driver of ﬁbrosis. During inﬂammation and
ﬁbrogenesis, HSCs undergo transdiﬀerentiation into activated
MFBs accompanied with cell proliferation. Several diﬀerent miRs
have speciﬁc roles during the process of HSC transdiﬀerentiation
in liver ﬁbrosis (Figure 8).
Moreover, miR-34a and -199 play pivotal roles in the initiation
of HSC transdiﬀerentiation (Roy et al., 2015). miR-34a, which
targets ASCL1, is upregulated during the initiation of liver
ﬁbrosis in a model of DMN-induced ﬁbrosis (Li et al., 2011).
The upstream target of miR-34a is the tumor suppressor p53
that can initiate cell cycle arrest, which explains the eﬀects on
HSC proliferation (Okada et al., 2014). Serum levels of miR-
34a were also reported to be increased in patients with NAFLD
(Cermelli et al., 2011). A hallmark study identiﬁed keymiRs using
miR arrays by comprehensively studying experimental ﬁbrosis
models in mice (Roderburg et al., 2011). Among these miRs,
miR-29b is part of a signaling nexus involving TGF-β- and NF-
κB-dependent signals in HSCs (Roderburg et al., 2011), while
miR-133a mediates TGF-β-dependent derepression of collagen
synthesis in HSCs (Roderburg et al., 2013). These and other
studies suggested circulating miR may be potentially a novel
diagnostic biomarker for liver ﬁbrosis progression (Roderburg
et al., 2012). For instance, members of the miR-199 and miR-200
family, namely miR-199a,−199a∗, −200a, and−200b, correlated
with the progression of liver ﬁbrosis both in murine models and
human patients (Murakami et al., 2011).
Besides being critical initiators of HSC activation and
ﬁbrogenesis, there are also miR, which exhibit therapeutic
potential due to their inhibiting eﬀects on HSC disease
progressing activation and which can therefore be designated as
antiﬁbrotic. The miR-29 was reported to down-regulate ECM
synthesis in mouse models and human patients by among others
targeting several collagen-associated genes (Bandyopadhyay
et al., 2011). Characterized by the sole inhibition of P4HA1,
the liver-speciﬁc miR-122 was found to reduce proliferation and
activation of HSCs (Li et al., 2013; Shah et al., 2013). Down-
regulation of cyclin E1 was shown for miR-195, and thereby,
proliferation of HSCswas reduced in humans (Sekiya et al., 2011).
Recently, miR-192 was identiﬁed as an important molecule in
the transdiﬀerentiation process of HSCs by Coll et al. (2015).
It was strongly downregulated in cirrhotic livers compared to
healthy organs as an early event during ﬁbrosis progression and
had a large number of 28 predicted target genes, based on an
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FIGURE 8 | Role of different micro-RNA during the process of HSC transdifferentiation in liver fibrosis. Quiescent HSCs can become activated by certain
miR during early fibrogenesis (miR-34a, -199, and -200), whereas the administration of others (e.g., miR-29, -122, and -195) might represent novel treatment
options for liver fibrosis. miR-192 expression is strongly reduced in early stages of HSC activation, whereas those miR that increase in HSCs during fibrosis (miR-21,
-33a, -125b-1, and -181) represent putative therapeutic targets in fibrosis therapy.
analysis of human HSCs. The authors found miR-192 to be
strongly downregulated (nearly abrogated) already during early
CCl4-based liver ﬁbrosis (Coll et al., 2015). These observations
put miR-192 into the role of a promising biomarker or target for
early ﬁbrosis.
After having progressed into activated, proliferating HSCs, the
cells were observed to express a variety of miR indicative for their
activation status. These molecules represent potential molecular
targets for interventions, such as miR21, which modulates ERK1
signaling in HSC activation and the EMT of hepatocytes via
inhibiting SPRY2 and HNF4α mRNA (Zhao et al., 2014). miR-
33a particularly increases during the progression of human and
murine liver ﬁbrosis in HSCs only. Toward their stimulation
with TGF-β, HSCs react with upregulation of miR-33a, a
regulator of lipid and cholesterol metabolism, which probably
acts through Smad7 (Huang et al., 2015). The expression of
miR125b-1 was described as being signiﬁcantly increased in
HSCs of liver ﬁbrosis patients (Coll et al., 2015). miR-181b,
which activates HSCs based on the phosphatase and tensin
homolog deleted on chromosome 10 (PTEN)/Akt pathway, and
further correlates with human liver disease progression (Yu et al.,
2015).
CLINICAL TRANSLATION OF
PRECLINICAL FINDINGS
Despite numerous innovative anti-ﬁbrotics in preclinical
settings, the number of those entering clinical studies is
limited. At present, the best option for ﬁbrosis treatment
remains in eliminating the underlying cause of liver disease.
For instance, antiviral therapies in virus hepatitis, alcohol
abstinence or lifestyle changes represent eﬀective antiﬁbrotic
measures in the respective liver diseases (Tacke and Trautwein,
2015).
Many preclinical studies suﬀer from the drawback that they
focus on single cells or molecules, which help to identify
mechanisms but ignore the complexity of biological systems. For
instance, IFN-α or IFN-γ act as eﬃcient anti-ﬁbrotics in vitro
(Mallat et al., 1995), but were not successful in the clinics
(Fernández et al., 2006; Di Bisceglie et al., 2008). Earlier attempts
to neutralize TGF-β suﬀer from a large number of eﬀects of
the cytokine on other cell types when administered parenterally.
Therefore, speciﬁcity is an important issue, which has to be
addressed more properly. For this aim, nanotechnological and
innovative formulations, which speciﬁcally target HSC-expressed
receptors such as the Rho kinase inhibitor Y27632 coupled to
mannose-6-phosphate, may point toward novel directions (van
Beuge et al., 2011).
Despite the fact that the existence of ﬁbrosis regression
represents a major source of hope for the success of novel
treatment options, it has to be considered further that many of
the standard models of hepatic rodent ﬁbrosis, such as CCl4-
mediated liver ﬁbrosis, is reversible, which is in big contrast
to human liver cirrhosis. It is therefore advisable that rodent
models with little degree of regression should be used as well.
Additionally, the time frame for human ﬁbrogenesis usually
comprises years but not weeks. Nevertheless, new compounds
targeting such “late events” are currently under investigation. The
antibody simtuzumab antagonizes LOXL2, which is an enzyme
that cross-links collagen ﬁbers as a late event in ﬁbrogenesis
(Barry-Hamilton et al., 2010).
Another challenge is the design of proper clinical trials,
including suitable endpoints for such trials. At the moment,
most trials rely on serial liver biopsies. Novel biomarkers, which
allow speciﬁc ﬁbrosis staging, and other non-invasive methods
are promising novel directions for monitoring the success of
antiﬁbrotic therapies (Schuppan and Pinzani, 2012). Progresses
in HSC targeting with nanotechnological formulations or
innovative molecules such as miR might help to ﬁnally bring
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novel personalized therapeutic strategies to the clinics (Schuppan
and Pinzani, 2012).
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